Hawaii SB3195 mandates Medicaid and Medicare Part D coverage for FDA-approved GLP-1 drugs for weight loss.

Hawaii SB3195 requires the Department of Human Services to cover certain GLP-1 drugs for weight loss under Medicaid and Medicare Part D. These drugs, including Saxenda, Wegovy, and Zepbound, are effective for treating obesity, a condition linked to diabetes and heart disease. The bill mandates coverage if the drugs are FDA-approved for weight loss, prescribed by a practitioner, and without prior authorization. The Department of Human Services must issue temporary rules by August 1, 2026, and permanent rules by January 1, 2028.

Hawaii SB3195 mandates Medicaid and Medicare Part D coverage for FDA-approved GLP-1 drugs for weight loss.

Hawaii SB3195 requires the Department of Human Services to cover certain GLP-1 drugs for weight loss under Medicaid and Medicare Part D. These drugs, including Saxenda, Wegovy, and Zepbound, are effective for treating obesity, a condition linked to diabetes and heart disease. The bill mandates coverage if the drugs are FDA-approved for weight loss, prescribed by a practitioner, and without prior authorization. The Department of Human Services must issue temporary rules by August 1, 2026, and permanent rules by January 1, 2028.